Scholarlink

<p>Using NSG mice grafted with H3122 non-small cell lung cancer cells, we compared outcomes from (1) continuous therapy with alectinib, (2) adaptive therapy where alectinib was cycled on and off based on a mouse’s tumor burden, and (3) no treatment. Adaptive therapy has proven successful in mouse models and clinical trials. The success of adaptive therapy improves when either there is density-dependent feedbacks favoring competition by sensitive over resistant cancer cells when therapy is off, or when the rate at which the population of cancer cells becomes more sensitive to therapy during periods of no treatment is faster than the rate at which resistance increases when on therapy. We found tumor growth rates were lowest under continuous therapy and highest under no therapy with adaptive therapy in between. We fitted the data to three separate game-theory models of resistance evolution where we let resistance be a quantitative trait consistent with resistance mechanisms to alectinib. All models successfully identified why adaptive therapy proved less successful than continuous: there was no evidence for favorable density-dependent feedbacks; and there was no significant difference in the rate of evolution towards or away from resistance when therapy was on or off.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Density dependence and evolvability limit adaptive therapy in non-small cell lung cancer mouse model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Mariyah Pressley,
  • Jessica J. Cunningham,
  • Luiza Simoes,
  • Robert A. Gatenby,
  • Joel S. Brown,
  • Stanislav Avdieiev

摘要

Using NSG mice grafted with H3122 non-small cell lung cancer cells, we compared outcomes from (1) continuous therapy with alectinib, (2) adaptive therapy where alectinib was cycled on and off based on a mouse’s tumor burden, and (3) no treatment. Adaptive therapy has proven successful in mouse models and clinical trials. The success of adaptive therapy improves when either there is density-dependent feedbacks favoring competition by sensitive over resistant cancer cells when therapy is off, or when the rate at which the population of cancer cells becomes more sensitive to therapy during periods of no treatment is faster than the rate at which resistance increases when on therapy. We found tumor growth rates were lowest under continuous therapy and highest under no therapy with adaptive therapy in between. We fitted the data to three separate game-theory models of resistance evolution where we let resistance be a quantitative trait consistent with resistance mechanisms to alectinib. All models successfully identified why adaptive therapy proved less successful than continuous: there was no evidence for favorable density-dependent feedbacks; and there was no significant difference in the rate of evolution towards or away from resistance when therapy was on or off.